Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
95% Confidence Interval
10%
Adjuvant Therapy
13%
Antiangiogenic Agents
13%
Anticore
19%
Antiproliferative Effect
9%
Antitumor Activity
14%
Bortezomib
13%
Cancer Cell Lines
19%
Cancer Cells
12%
Cancer Therapy
8%
Cetuximab
23%
Circulating Tumor DNA (ctDNA)
39%
Clinical Trials
13%
Colorectal Cancer
41%
Colorectal Cancer Patients
13%
Core 1 O-glycans
19%
Disease Control
13%
Disease-free Survival
10%
Epidermal Growth Factor Receptor Inhibitors (EGFRI)
55%
Epidermal Growth Factor Receptor-tyrosine Kinase Inhibitor (EGFR-TKI)
8%
Erlotinib
9%
First-in-human
13%
Glycan Targeting
13%
Human Leukocyte Antigen
19%
Immune Checkpoint Blockade
13%
Immune Checkpoint Inhibitors
8%
Inpatient Treatment
13%
KRAS mutation
13%
Loss of Heterozygosity
17%
MD Anderson Cancer Center
9%
Metastatic Colorectal Cancer (mCRC)
31%
Microsatellite Instability-high (MSI-H)
12%
Minimal Residual Disease
26%
Monoclonal Antibody
42%
NEO-201
33%
Non-small Cell Lung Cancer (NSCLC)
18%
Overall Survival
15%
Pancreatic Cancer
8%
Patients with Colorectal Cancer
22%
Phase 1 Clinical Trial
13%
Phase II Trial
13%
RAS mutation
8%
Refractory Solid Tumors
13%
Retrospective Analysis
14%
TAS-102
13%
Treatment Refractory
14%
Treatment Termination
13%
Tumor
14%
Tumor Cells
9%
Vascular Endothelial Growth Factor
25%
Medicine and Dentistry
Adjuvant Therapy
13%
Antineoplastic Activity
10%
Antiproliferative Activity
10%
Biological Marker
10%
Cancer Cell Line
7%
Cancer Model
6%
Cancer Research
7%
Carcinogenesis
6%
Cell-Free DNA
6%
Chemotherapy
25%
Circulating Tumor DNA
37%
Clinical Trial
41%
Codon
7%
Colorectal Carcinoma
100%
Cyclophosphamide
6%
Cytotoxic Agent
8%
Disease Free Survival
10%
Diseases
32%
Epidermal Growth Factor Receptor
23%
Epidermal Growth Factor Receptor Kinase Inhibitor
13%
Erlotinib
6%
Gene Expression Profiling
7%
Genetics
9%
Glycan
13%
Heterozygosity
18%
Histone Deacetylase
6%
Human Leukocyte Antigen
20%
Immune Checkpoint Blockade
19%
Immunotherapy
14%
Malignant Neoplasm
15%
Metastatic Colorectal Cancer
30%
Microsatellite Instability
14%
Minimal Residual Disease
26%
Monoclonal Antibody
21%
Neoplasm
18%
Overall Survival
16%
Pancreas Cancer
11%
Personalized Medicine
7%
Pharmacokinetic
8%
Phase I Trials
8%
Phase II Trials
13%
Predictive Marker
7%
Ras Signaling
8%
Recurrent Disease
8%
Selumetinib
13%
Solid Malignant Neoplasm
20%
Ticilimumab
6%
Tumor
15%
Tumor Biopsy
6%
Xenograft
8%
Pharmacology, Toxicology and Pharmaceutical Science
Adenosine Phosphate
6%
Angiogenesis Inhibitor
13%
Antitumor Activity
10%
Bevacizumab
6%
Binimetinib
6%
Biological Marker
6%
Bortezomib
6%
Cancer Model
9%
Cediranib
6%
Cetuximab
15%
Chemotherapy Regimen
13%
Circulating Tumor DNA
6%
Clinical Pharmacokinetics
6%
Clinical Trial
32%
Colon Carcinoma
9%
Colorectal Carcinoma
29%
Cyclophosphamide
6%
Cytotoxic Agent
9%
Digestive System Cancer
6%
Diseases
17%
Epidermal Growth Factor Receptor
49%
Epidermal Growth Factor Receptor Kinase Inhibitor
40%
Erlotinib
12%
Fluorouracil
6%
Gefitinib
8%
Glycan
13%
Hydroxychloroquine
6%
Immunotherapy
6%
Leukocyte Antigen
13%
Lung Cancer
12%
Malignant Neoplasm
49%
Metastatic Colorectal Cancer
6%
Minimal Residual Disease
6%
Monoclonal Antibody
24%
Neoplasm
27%
Non Small Cell Lung Cancer
21%
Pancreas Cancer
6%
Phase I Trials
7%
Phase II Trials
6%
Selumetinib
6%
Small Interfering RNA
6%
Solid Malignant Neoplasm
19%
Sorafenib
6%
Tumor Growth
8%
Vandetanib
14%
Vasculotropin
19%
Vasculotropin Receptor
11%
Vasculotropin Receptor 1
6%
Volume of Distribution
6%
Vorinostat
6%